AI Article Synopsis

  • - Mitochondria play vital roles in energy production and metabolism in cells, and their functions are often altered in cancer to support tumor growth; cancer stem cells (CSCs) are particularly reliant on mitochondrial activity for their survival and resistance to treatment.
  • - Small molecule ONC201, which activates mitochondrial caseinolytic protease (ClpP), leads to mitochondrial dysfunction in breast cancer cells, inhibiting their growth and CSC functions more effectively than other treatments.
  • - ClpP agonists disrupt several metabolic pathways essential for CSC survival, including oxidative phosphorylation and one-carbon metabolism, ultimately reducing CSC functions and offering a promising therapeutic strategy in breast cancer treatment.

Article Abstract

Unlabelled: Mitochondria are multifaceted organelles which are important for bioenergetics, biosynthesis and signaling in metazoans. Mitochondrial functions are frequently altered in cancer to promote both the energy and the necessary metabolic intermediates for biosynthesis required for tumor growth. Cancer stem cells (CSCs) contribute to chemotherapy resistance, relapse, and metastasis. Recent studies have shown that while non-stem, bulk cancer cells utilize glycolysis, breast CSCs are more dependent on oxidative phosphorylation (OxPhos) and therefore targeting mitochondria may inhibit CSC function. We previously reported that small molecule ONC201, which is an agonist for the mitochondrial caseinolytic protease (ClpP), induces mitochondrial dysfunction in breast cancer cells. In this study, we report that ClpP agonists inhibit breast cancer cell proliferation and CSC function and . Mechanistically, we found that OxPhos inhibition downregulates multiple pathways required for CSC function, such as the mevalonate pathway, YAP, Myc, and the HIF pathway. ClpP agonists showed significantly greater inhibitory effect on CSC functions compared with other mitochondria-targeting drugs. Further studies showed that ClpP agonists deplete NAD(P)+ and NAD(P)H, induce redox imbalance, dysregulate one-carbon metabolism and proline biosynthesis. Downregulation of these pathways by ClpP agonists further contribute to the inhibition of CSC function. In conclusion, ClpP agonists inhibit breast CSC functions by disrupting mitochondrial homeostasis in breast cancer cells and inhibiting multiple pathways critical to CSC function.

Significance: ClpP agonists disrupt mitochondrial homeostasis by activating mitochondrial matrix protease ClpP. We report that ClpP agonists inhibit cell growth and cancer stem cell functions in breast cancer models by modulating multiple metabolic pathways essential to cancer stem cell function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645232PMC
http://dx.doi.org/10.1158/2767-9764.CRC-22-0142DOI Listing

Publication Analysis

Top Keywords

clpp agonists
32
breast cancer
20
agonists inhibit
16
cancer stem
16
cancer cells
16
csc function
16
protease clpp
12
stem cell
12
mitochondrial homeostasis
12
cancer
11

Similar Publications

Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Infection.

J Med Chem

January 2025

State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Peritonitis caused by poses a severe threat to patients with end-stage renal failure. Treating multidrug-resistant infections requires the use of antibiotics with diverse mechanisms of action. Caseinolytic protease P (ClpP) is a promising antibacterial target; however, selective activation of (ClpP) over human ClpP (ClpP) remains challenging.

View Article and Find Full Text PDF

Structure-guided development of selective caseinolytic protease P agonists as antistaphylococcal agents.

Cell Rep Med

December 2024

State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China. Electronic address:

Methicillin-resistant Staphylococcus aureus is a ubiquitous pathogen, posing a serious threat to human health worldwide. Thus, there is a high demand for antibiotics with distinct targets. Caseinolytic protease P (ClpP) is a promising target for combating staphylococcal infections; however, selectively activating S.

View Article and Find Full Text PDF

Discovery of CLPP-1071 as an Exceptionally Potent and Orally Efficacious Human ClpP Activator with Strong In Vivo Antitumor Activity.

J Med Chem

December 2024

Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tsuihang New District, Zhongshan 528400, Guangdong, China.

caseinolytic protease P (ClpP) is essential for maintaining mitochondrial proteome homeostasis, and its activation is increasingly recognized as a promising cancer therapy strategy. Herein, based on structure-guided drug design, we discovered a series of potent ClpP activators by introducing a methyl group to the imipridone scaffold of the ClpP activator in Phase III clinical trials. Through structural optimization of the lead compound, the most optimal compound, , exhibited exceptionally potent ClpP agonistic activity (EC = 23.

View Article and Find Full Text PDF
Article Synopsis
  • Mitochondria-targeting agents, or mitocans, are becoming promising cancer treatments due to their effects on cancer cell metabolism and apoptosis, with ONC212 being a key compound studied.
  • Despite ONC212 showing effectiveness in inducing cell death in cancer cells like HeLa and A549, its specific mechanisms are still not fully understood.
  • The study reveals that ONC212 triggers apoptotic features without typical mitochondrial changes and can enhance cell death when combined with a Bcl-2/Bcl-xL inhibitor, indicating its potential for use in combination therapies for tumors with impaired mitochondrial signaling.
View Article and Find Full Text PDF

Oxidative phosphorylation is an essential metabolic process for cancer proliferation and therapy resistance. The ClpXP complex maintains mitochondrial proteostasis by degrading misfolded proteins. Madera Therapeutics has developed a class of highly potent and selective small-molecule activators (TR compounds) of the ClpXP component caseinolytic peptidase proteolytic subunit (ClpP).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!